netFormulary Dorset NHS
The Dorset Formulary has been developed in associations with
NHS Dorset Clinical Commissioning Group
Dorset County Hospital NHS Foundation Trust
Dorset Healthcare University NHS Foundation Trust
Poole Hospital NHS Foundation Trust
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
 
 Introduction
Welcome to the Dorset Formulary

Useful Links

Covid-19 Resources

SPS Care Home Resource Hub

 

GOV.UK guidance on re-use of a medicine in a care home or hospice

CCG guidance to support medicines re-use

 Guidance for GP practices on sharing details of patients with shielded status with community pharmacy  Guidance for patients taking SGLT2 inhibitors

FAQ for prescribing during the Covid-19 pandemic

Antibiotics

Palliative care

NICE NG165: Covid-19 Rapid Guideline - managing suspected or confirmed penumonia in adults in the community

NICE NG163: Covid-19 Rapid Guideline - managing symptoms (including end of life) in the community

Electronic Repeat Dispensing (eRD) resource page
NICE NG166: Covid-19 Rapid Guideline - Severe Asthma

Managing Vitamin B12 Injections during COVID

Guidance on the safe switching of warfarin to DOACs (NHSE March 2020)

Guidance for Housebound Patients on Warfarin

BTS-information-respiratory-inhalers

COVID-19 Interim Guidance for prescribers around COPD & Asthma Rescue Packs

 

COVID 19: Temporary guidance on Denosumab

Useful resources from SPS including drug monitoring for lithium, warfarin, DMARDs etc. during COVID 19

Prescribing in primary and community care during COVID 19 outbreak

Links from Document below

NMP Change of Circumstamces Form

Instructions For Prescriber Setting

 

Support to move from MDS to original packs

Care Homes

Domicillary Care

   

 

Dorset Medicines Advisory Group (DMAG)

(For previous DMAG summaries please see further below)

DMAG Summary June 2020 DMAG Annual Report 2018-2019

Drug Decision Making Process

Traffic Light Categorisation

Formulary Proposal Form Shared Care Guideline Template

Primary Care

Opioid Resource Pack

SCAN Guidelines (Antibiotics)

Understanding your urine microbiology results (MSU)

SPS guidance on alternatives to solid dosage forms

CQC matrix

Medicines Optimisation Plan (including audits and savings plan)

Dorset CCG Medicines Standards

NHSE Medicines Shortage Guidance

SPS - Shortages

DHSC - Shortages

GSK shortages

MIMS Drug shortages - live tracker

Private Prescription Guidance

Private Prescription – Items Cheaper Than a Prescription Charge 

NHSE OTC patient information leaflet

NHSE OTC Letter for GPs

NHSE OTC support document

Medicines Matters: mechanisms for prescribing, supply and administration of medicines

Template Letter to Decline prescribing of "red" drugs in Primary Care

Template Letter to Decline Prescribing of "non-formulary" drugs in Primary Care 

 Resources for Specials Prescribing

 

Over the counter items - GP guide to self care (PrescQIPP log in required)

 

Secondary Care

Individual Funding Requests (NHSE)

CCG Notification of High Cost Excluded Drugs

Cancer Drug Fund (CDF) List

 
NHS England High Cost Drug List

Individual Funding Requests (CCG)

The Manual NHS England

 

Useful Websites

Yellow Card Scheme

Polypharmacy Formulary Chapter

NICE Evidence Search/ BNF

Drug Tariff

NHS Choices Patient Medicine Leaflets

Electronic Medicines Compendium (eMC)

OTC Directory

CCG Incident Reporting Tool

SPS: Excipients: What are the general considerations for vegan patients? Central Alerting System (CAS) homepage  Sexual Health Dorset - Pathways  

Electronic Repeat Dispensing (eRD) resource page

Dorset Medicines Advisory Group (DMAG) Historical Summaries of Recommendations

DMAG Summary March/April 2020 DMAG Summary January 2020
DMAG Summary November 2019 DMAG Summary September 2019

 

News Feed

19th May 2020

Flu Season Has Ended- Please see details Here

Guidance documents can be found here for out of season influenza prescribing. Alternatively search the term "FLUOOS" in the search bar.


Ibuprofen and coronavirus (COVID-19)

The Commission of Human Medicines (CHM) has been asked to review the safety of ibuprofen in patients with COVID-19. The Commission on Human Medicines’ Expert Working Group on coronavirus (COVID-19) has concluded that there is currently insufficient evidence to establish a link between use of ibuprofen, or other non-steroidal anti-inflammatory drugs (NSAIDs), and contracting or worsening of COVID-19.

Patients can take paracetamol or ibuprofen when self-medicating for symptoms of COVID-19, such as fever and headache, and should follow NHS advice if they have any questions or if symptoms get worse.

For full details see here.


Class 2 Drug Alert: Emerade 300mcg pre-filled syringe - patient level recall

Pharmaswiss Česka republika s.r.o. (an affiliate of Bausch & Lomb UK Limited) is recalling all unexpired batches of Emerade 300 microgram auto-injectors (also referred to as pens) from patients due to an error in one component of the auto-injector believed to cause some pens to fail to activate and deliver adrenaline.  The full alert is available here. 
 
Healthcare professionals (GP Practices, Pharmacies) should contact patients and carers with Emerade 300mcg pens, to inform them of the recall information contained within this alert. Additional advice has also been provided for patients with Emerade 500mcg pens, which are not currently subject to a recall due to insufficient supplies of alternative brands of pens. 
 
No further supplies of Emerade will be available on the UK market until the issue has been resolved, therefore patients and carers should be appropriately trained to use other brands.

Class 2 Medicines Recall: Esmya 5mg tablets, EU/1/12/750/001-5, (EL(20)A/16)

See full drug alert here

Gedeon Richter (UK) Ltd is recalling all unexpired stock of Esmya 5 mg tablets from patients, pharmacies and wholesalers following a new case of liver failure requiring liver transplant in a patient taking the medicine.

Advice for healthcare professionals

Contact patients who have been supplied Esmya and ask them to stop taking their medication as soon as possible and return any unused medicine to their pharmacy. All patients currently being treated with Esmya/ulipristal acetate for uterine fibroids should contact their doctor for advice about other possible treatments for uterine fibroids.

Stop supplying the above products immediately and remove from the shelves within your store. Quarantine all remaining stock and return it to your supplier using your supplier’s approved process.

Stop prescribing Esmya or generic ulipristal acetate for the treatment of uterine fibroids. No new patients should start treatment with the medicines, which has been suspended throughout the EU during the review. Consider other treatment options as appropriate.

Liver function testing should be performed 2- 4 weeks after treatment has stopped as described in the product information for the medicines.

Healthcare professionals should alert patients to immediately report signs and symptoms of liver injury (such as nausea, vomiting, right hypochondrial pain, anorexia, asthenia, jaundice) which could occur after stopping treatment.


Class 2 Medicines Recall: LEO Laboratories Ltd, Picato 150 mcg/g gel

See full drug alert here

LEO Laboratories Ltd (T/A LEO Pharma) is recalling all unexpired stock of the above products from pharmacies and wholesalers as a precautionary measure due to concerns on the possible risk of skin malignancy. The recall is a precautionary measure following the suspension of the marketing authorisation of Picato (ingenol mebutate), while investigations are ongoing.

Advice for healthcare professionals

  • Stop supplying the above products immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

  • Stop prescribing Picato and consider other treatment options as appropriate. For patients who have recently been prescribed Picato, advise patients to be vigilant for any skin lesions developing and to seek medical advice promptly should any occur.

 


Magnesium Hydroxide Mixture Shortage

Due to difficulties obtaining raw materials, there are currently no stocks of magnesium hydroxide mixture. The earliest anticipated return date is Feb 2020. Alternative laxatives will be required in the interim (lactulose and macrogol being alternative osmotic laxatives). 


>>> more news


Getting started: Use the search tool to find medicine of interest or browse by BNF chapter using the 'Chapters' Menu at top of page.

The Dorset Formulary aims to provide information on medicines supporting safe, evidence-based, cost-effective practice. Whilst the formulary contains links to relevant policies and guidelines, the prescriber retains the responsibility for the appropriate use of this information.

For further information on the development of the Dorset Formulary and participating organisations, please go to the About page. 

Comments about any aspect of the formulary can be made by using the feedback tab at the top of this page.


NetFormulary
   Visits = 224493
   Last updated: 16/07/2020 15:39:09..